Non-invasive image-guided breast brachytherapy (NIIGBB) [Patient Data Registry Excerpts] David E. Wazer, MD Tufts University School of Medicine Brown University.

Slides:

Advertisements

Similar presentations

Selected Findings from a Nationwide Analysis of State Laws Affecting the Use of Immunization Standing Orders* Sara Rosenbaum AcademyHealth ARM June 2,

Advertisements

Bruce Siegel MD MPH, Marcia Wilson MBA, Khoa Nguyen MPH, Marsha Regenstein PhD Academy Health June 6, 2004 Improving the Performance of the Safety Net:

Sandra G. Adams, MD, MS Pulmonary Diseases / Critical Care Medicine University of Texas Health Science Center at San Antonio South Texas Veterans Healthcare.

Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.

Patrick St. Louis, PhD CPOCT Chair Refining Point of Care Testing Strategies for Critical and Emergency Care 21st International Symposium Quebec City,

Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.

Marco Island Marriott Beach Resort, Florida July 15, 2014.

LASER-ASSISTED LIPOSUCTION AND SUTURE SUSPENSION OF FLAP TECHNIQUE

Non-Melanoma Skin Cancer Treated with Electronic Brachytherapy: Results at Two Years Ajay Bhatnagar MD, MBA Cancer Treatment Services Arizona Casa Grande,

San Antonio Breast Cancer Symposium 2007 Highlights – Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford.

Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.

High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.

Response Evaluation of Gastrointestinal Stromal Tumors (GIST)

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Medicare Coverage of Technology, How Evidence-Based, Timely, and Flexible? June 10, 2008 Peter J. Neumann, Maki S. Kamae, Jennifer A. Palmer.

MASCC Survey for Palliative Care Mellar P Davis MD FCCP FAAHPM.

Desirable Surveillance Network National Prion Disease Pathology Surveillance Center Locations Regularly Performing.

Proton Therapy for Chondrosarcomas of the Skull Base and Cervical Spine: Long-term Experience at Loma Linda University Medical Center D. Y. Kim 2, R. W.

The National Program of Cancer Registries: Enhancing Cancer Incidence Data … Hannah K. Weir, PhD Division of Cancer Prevention and Control Centers for.

High Value Primary Care: New Evidence on the Excellent Return on Investment in Primary Care Commonwealth Fund and Alliance for Health Reform Briefing December.

Michelle J.K. Osterman, M.H.S. Joyce A. Martin, M.P.H. National Center for Health Statistics Extending Our Reach Through Partnerships June 2-6, 2013 Phoenix,

Photodynamic Therapy for breast cancer

MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

MOLECULAR SUBTYPES IN LEIOMYOSARCOMA Matt van de Rijn, Stanford University Xiangqian Guo 1, Vickie Young Jo 2, Anne M. Mills 3,Shirley X Zhu 1, Cheng-Han.

Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.

JUPITER MEDICAL CENTER A not-for-profit 283-bed community Medical Center consisting of 163 private acute care hospital beds and 120 long-term care beds,

Improving the Care of Patients with CHF in a Rural Area Lee Greer, MD Geriatric Medicine North Mississippi Medical Clinics, Inc.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

“Best” Practices In Outcomes Research ISW 2013 Helsinki, Finland Christine Laronga MD FACS Comprehensive Breast Program H. Lee Moffitt Cancer Center.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

1 ASCO Annual Meeting 2013 Poster presentation January 2013.

Corresponding author Name; 2015 North Jefferson St; Three-Year Analysis of Urinary Toxicity in Two Prospective Trials.

Laurie Cuttino MD, Dorin Todor PhD, Douglas Arthur MD, Rohini George, Lynn Pacyna CMD Medical College of Virginia Campus Department of Radiation Oncology.

New York University Department of Radiation Oncology Prospective Randomized Trial of Prone Accelerated Intensity Modulated Whole Breast Radiation Therapy.

We retrospectively analyzed 58 patients with ONSM treated between on a dedicated 6 MV stereotactic LINAC. All cases were discussed in a multidisciplinary.

Robert Taylor MD, PhD, Alexander Whitley MD, PhD, Craig Baden MD, Javier Lopez-Araujo MD, Sui Shen PhD, O. Lee Burnett MD, Jennifer De Los Santos MD and.

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Percent of adults ages 19–64 Exhibit 1. More Than Half of Adults in Florida and Texas Were Uninsured or Underinsured in 2012 Uninsured during the year*

Toxicity and Cosmesis from RTOG 95-17: A Phase I/II Trial to Evaluate Brachytherapy as the Sole Method of Radiation Therapy for Stage I and II Breast Carcinoma.

Georgia: National Leader in Training an SBIRT Workforce J. Paul Seale, MD Family Physician Professor & Director of Research Dept. of Family Medicine Navicent.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Care Management: Developing an Integrated Model of Care.

 Gy  Decreased fibrosis  Enhanced local control  Deep seeded tumors isch&source=hp&biw=1366&bih=624&q=radia.

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.

UNIVERSAL SURVIVAL CURVE AND SINGLE FRACTION EQUIVALENT DOSE: USEFUL TOOLS IN UNDERSTANDING POTENCY OF ABLATIVE RADIOTHERAPY CLINT PARK, M.D. M.S., LECH.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

A Head-to-Head Comparison of the Sport Concussion Assessment Tool 2 (SCAT2) and the Military Acute Concussion Evaluation (MACE) 1 Department of Neurosciences.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Top 3 European countries? 1.England/Britain 2.France 3.Spain.

1st Year General Cardiology Fellows

Hypofractionated radiotherapy for breast cancer

Evaluating Quality in Clinical Cancer Research: The M. D

Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.

Parkinson’s progression markers initiative

سرطان الثدي Breast Cancer

Adults in California and New York Reported Lower Rates of Cost-Related Access Problems Than Those in Florida and Texas Percent of adults ages 19–64 U.S.

New CHEST Editorial Board Members

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

From Out of the Desert Blooms a Jewel of the Southwest: A Commentary on the History of Mayo Clinic in Arizona Michele Y. Halyard, MD Mayo Clinic Proceedings

Particle Therapy Cooperative Group North America Annual Conference

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,

Clinical Outcomes after Proton Partial Breast Radiotherapy for Early Stage- Hormone Receptor Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial.

Presentation transcript:

Non-invasive image-guided breast brachytherapy (NIIGBB) [Patient Data Registry Excerpts] David E. Wazer, MD Tufts University School of Medicine Brown University School of Medicine

A multi-institutional assessment of the feasibility, implementation, and early clinical results with noninvasive image-guided breast brachytherapy for tumor bed boost. Subarna Hamid 1,2, Kathy Rocchio 2, Douglas Arthur 3, Robyn Vera 3, Sandra Sha 4, Michele Jolly 4, Sean Cavanaugh 5, Eric Wooten 5, Rashmi Benda 6, Brad Greenfield 6, Bradley Prestidge 7, Scot Ackerman 8, Robert Kuske 9, Coral Quiet 9, Margie Snyder 9 and David Wazer 1,2. 1 Tufts Medical Center, Boston, MA. 2 Brown University, Rhode Island Hospital, Providence, RI. 3 Virginia Commonwealth University, Richmond, VA. 4 Central Florida Cancer Institute, Davenport, FL. 5 Atlanta Oncology Associates, Hawkinsville, GA. 6 Boca Raton Community Hospital, Boca Raton, FL. 7 Texas Cancer Clinic, San Antonio, TX. 8 First Coast Oncology, Jacksonville, FL. 9 Arizona Breast Cancer Specialists, Phoenix, AZ 101 patients; median follow-up = 9 months (3-17 mos)

SKIN TOXICITY Grade 0Grade 1Grade 2 Acute Skin (1-3 wks) Intermediate Skin (4-26 wks) Late-interm Skin (>26 wks) 87130

SUBCUTANEOUS TOXICITY Grade 0Grade 1Grade 2 Acute SubQ (1-3 wks) Intermediate SubQ (4-26 wks) Late-interm SubQ (>26 wks)87130

% Excellent% good % fair% poor Boost upfront During WBRT Preliminary cosmesis rating for ≤ 6month follow-up…

Preliminary comparison of patient discomfort and ≤ 6month FU cosmesis

Preliminary Results

Preliminary Conclusions These data indicate that NIIGBB is feasible and can be consistently implemented in a broad array of practice settings. Preliminary evaluation suggests that NIIGBB is associated with acceptably mild normal tissue toxicity and favorable early cosmetic results. The application of NIIGBB before completion of WBRT may be associated with better patient tolerance at the expense of slightly less favorable cosmetic outcome. These data indicate that NIIGBB is feasible and can be consistently implemented in a broad array of practice settings. Preliminary evaluation suggests that NIIGBB is associated with acceptably mild normal tissue toxicity and favorable early cosmetic results. The application of NIIGBB before completion of WBRT may be associated with better patient tolerance at the expense of slightly less favorable cosmetic outcome.

Thank you